A Closer Look at the TROPION-Breast02 Findings

Infographic

The panel reviews the TROPION-Breast02 findings, offering equipoise alongside the prior discussion of ASCENT-03. Panelists walk through the trial's progression-free and overall survival results against an investigator's choice monotherapy control arm, while noting that the absence of crossover shapes how the survival data should be interpreted. The discussion highlights the notably high objective response rate observed, its relevance for patients with high disease burden who need a rapid response, and how response rate, duration of response, and PFS2 fit together when evaluating clinical benefit. Panelists also note that a meaningful proportion of control-arm patients went on to receive subsequent ADC therapy, adding real-world texture to the longer-term follow-up. Throughout, the faculty emphasize that inherent design differences make direct superiority claims difficult, while the data overall reinforce confidence in the first-line ADC strategy. Viewers come away with a balanced understanding of the evidence supporting this approach.